Ryan Richardson - BIONTECH MD Officer
| B1NT34 Stock | BRL 44.46 0.07 0.16% |
Insider
Ryan Richardson is MD Officer of BIONTECH SE DRN
| Age | 44 |
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
BIONTECH Management Efficiency
The company has return on total asset (ROA) of 0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BIONTECH's management efficiency ratios could be used to measure how well BIONTECH manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susie Lisa | Vertex Pharmaceuticals Incorpor | N/A | |
| Daniel Maller | BeiGene | N/A | |
| Nia Tatsis | Vertex Pharmaceuticals Incorpor | N/A | |
| Wang Lai | BeiGene | 46 | |
| Kevin Mannix | BeiGene | N/A | |
| Ian Estepan | Sarepta Therapeutics | 47 | |
| Mi Zhou | BeiGene | N/A | |
| Melissa Moore | Moderna | N/A | |
| Xiaodong Wang | BeiGene | 60 | |
| Gerald Bruce | Vertex Pharmaceuticals Incorpor | N/A | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| Timothy Lee | Ascendis Pharma AS | N/A | |
| Jeffrey Leiden | Vertex Pharmaceuticals Incorpor | 63 | |
| Julia Wang | BeiGene | 52 | |
| Mike Tirozzi | Vertex Pharmaceuticals Incorpor | N/A | |
| Terrence Kearney | Vertex Pharmaceuticals Incorpor | 64 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 45 | |
| Ourania Tatsis | Vertex Pharmaceuticals Incorpor | 52 | |
| Diana McKenzie | Vertex Pharmaceuticals Incorpor | 54 | |
| Jan Mikkelsen | Ascendis Pharma AS | 63 | |
| Douglas Esq | Sarepta Therapeutics | 60 | |
Management Performance
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 |
BIONTECH SE DRN Leadership Team
Elected by the shareholders, the BIONTECH's board of directors comprises two types of representatives: BIONTECH inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIONTECH. The board's role is to monitor BIONTECH's management team and ensure that shareholders' interests are well served. BIONTECH's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIONTECH's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein, CFO Board | ||
| Sylke Maas, VP Strategy | ||
| James Ryan, Sr Counsel | ||
| Michael Boehler, MD Communications | ||
| Ryan Richardson, MD Officer | ||
| Sierk Poetting, COO MD | ||
| Pr MD, CoFounder Board | ||
| Ozlem MD, Chief CoFounder | ||
| Sean Marett, Chief Officer |
BIONTECH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIONTECH a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 165.09 B | |||
| Shares Outstanding | 3.88 B | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 12.63 X | |||
| Revenue | 18.98 B | |||
| Gross Profit | 16.07 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BIONTECH Stock
BIONTECH financial ratios help investors to determine whether BIONTECH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIONTECH with respect to the benefits of owning BIONTECH security.